Role of PGE2 Receptors in Mouse Skin Cancer
Role of PGE2 Receptors in Mouse Skin Cancer
批准号:
7594028
负责人:
Robert Langenbach
金额:
$79.32万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AgonistApoptosisApoptoticCCL4 geneCell Surface ReceptorsComplexCyclic AMP-Dependent Protein KinasesDataDevelopmentDinoprostoneDockingEpidemiologic StudiesFamilyGoalsHumanImmunoprecipitationIndomethacinMalignant NeoplasmsMediatingModelingMusNumbersPTGS2 genePapillomaProductionProstaglandin ProductionProstaglandin-Endoperoxide SynthaseProstaglandinsProtein KinaseProteinsProto-Oncogene Proteins c-aktRoleSeriesSignal PathwaySignal TransductionSignal Transduction PathwaySkinSkin CancerSkin PapillomaUV inducedUltraviolet B RadiationWild Type Mousearrestin Bcyclooxygenase 1cyclooxygenase 2human WFDC2 proteininhibitor/antagonistkeratinocyteprogesterone 11-hemisuccinate-(2-iodohistamine)prostaglandin EP2 receptorprostanoid receptor EP1receptortumorigenesis
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The major goal of the study was the elucidation of the role of prostaglandin E2 (PGE2) receptors (EP) in chemically and UV induced mouse skin tumorigenesis. Epidemiological studies in humans have
confirmed an important role of PGs, including PGE2, in a variety of cancers including skin cancer. PGE2 produced via the cyclooxygenases (COX-1/COX-2) act on four different cell surface receptors (EP 1, -2, -3, -4), which belong to the family of GPCRs.
In one series of studies, the mouse skin initiation/promotion model was used to investigate the contribution of the PGE2 receptors, EP2 and EP4, in papilloma development. Indomethacin was used to inhibit epidermal PG production and reduced papilloma formation about 60%. In indomethacin treated mice the EP2 agonist restored papilloma formation to TPA treatment levels, but the EP4 agonist was ineffective. In papillomas, the EP2 agonist increased Ras activation and levels as well as c-AMP, p-Src, p-EGFr, p-Erk and p-Akt levels. Treatment of papillomas with EGFr (Ag1478) or Src (PP2) inhibitors demonstrated that p-EGFr was downstream of p-Src. Ag1478 also inhibited the activation of Ras, Erk and AKT. EP2s role in papilloma development was confirmed by the observations that EP2 -/- mice showed a 60% reduction in papilloma numbers and reduced activation of Ras, Src, AKT and Erk. Immunoprecipitation of p-Src or EP2 indicated the presence of an EP2-b-arrestin1/2-p-Src complex in papillomas of wild type. B-arrestin can contribute to EP2 internalization as welll as serve as a docking protein and facilitate EP2 signaling. The data indicate that PGE2 acting via EP2 activates signal transduction pathways that can contribute to mouse skin papilloma development.
In a second serries of studies, the roles of EP2 and EP4 on UV induced skin damage was investigated. Wild type (WT) and COX-2-/- mice were acutely treated with UVB (5 kJ/m2) and apoptotic signaling pathways compared. Following exposure, apoptosis was 2.5-fold higher in COX-2-/- compared to WT mice. Because prostaglandin (PG) E2 is the major UV-induced PG and manifests its activity via four receptors, EP1 to 4, possible differences in EP signaling were investigated in WT and COX-2-/- mice. Following UVB exposure, protein levels of EP1, EP2, and EP4 were elevated in WT mice, but EP2 and EP4 levels were 50% lower in COX-2-/- mice. Activated cAMP-dependent protein kinase (PKA) and Akt are downstream in EP2 and EP4 signaling, and their levels were reduced in UVB-exposed COX-2-/- mice. Furthermore, p-Bad (Ser136 and Ser155), anti-apoptotic products of activated Akt and PKA, respectively, were significantly reduced in UVB-exposed COX-2-/- mice. To further study EP2 and EP4s roles, UVB-exposed CD-1 mice were topically treated with indomethacin to block endogenous PGE2 production, and PGE2, an EP2 agonist or an EP4 agonist applied. Indomethacin reduced PKA and Akt activation about 60%, but PGE2 and the agonists restored their activities. Furthermore, both agonists decreased apoptosis in COX-2-/- mice by 50%. The data suggest that COX-2 generated PGE2 has anti-apoptotic roles in UVB-exposed mouse skin that involves EP2 and EP4 mediated signaling that reduced keratinocyte apoptosis.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Roles Of Cyclooxygenase-1 And -2 In UV-Induced Skin Canc
-
批准号:6546703
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Effects Of Deficiency Of COX-1 or COX-2 On Chemically-In
-
批准号:6546704
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Roles of cyclooxygenase 1 & 2 in UV induced skin cancer
-
批准号:6413337
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Role of PGE2 Receptors in Mouse Skin Cancer
-
批准号:8336639
-
项目类别:
-
资助金额:$55.4万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
The roles of the COXs in normal physiology and pathology
-
批准号:7161817
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
The roles of the COXs in normal physiology and in pathological conditions
-
批准号:7967956
-
项目类别:
-
资助金额:$46.78万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
The Knockout of the Mouse Muc5ac
-
批准号:8734152
-
项目类别:
-
资助金额:$12.08万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Role of PGE2 Receptors in Mouse Skin Cancer
-
批准号:8553785
-
项目类别:
-
资助金额:$42.94万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
The Knockout of the Mouse Muc5ac
-
批准号:7594029
-
项目类别:
-
资助金额:$45.76万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Effects of COX-1 or COX-2 Deficiency on Mouse Skin Cancer
-
批准号:7593871
-
项目类别:
-
资助金额:$18.3万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Effects of COX-1 or COX-2 Deficiency on Mouse Skin Cancer
-
批准号:8148987
-
项目类别:
-
资助金额:$20.64万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
The roles of the COXs in normal physiology and in pathological conditions
-
批准号:8148983
-
项目类别:
-
资助金额:$35.38万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Deficiency of COX 1 or 2 on chemical intestinal cancer
-
批准号:6413340
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Effect of COX-1 or COX-2 Deficiency on Epidermal Differe
-
批准号:6546705
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Mouse Model--Targeted Gene Knock-Out of Prostaglandin Sy
-
批准号:6546698
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Role of PGE2 Receptors in Mouse Skin Cancer
-
批准号:7968228
-
项目类别:
-
资助金额:$56.81万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Effects of COX-1 or COX-2 Deficiency on Mouse Skin Cancer
-
批准号:8734054
-
项目类别:
-
资助金额:$12.08万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
The roles of the COXs in normal physiology and in pathological conditions
-
批准号:8734050
-
项目类别:
-
资助金额:$42.29万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
Effects of COX-1 or COX-2 Deficiency on Mouse Skin Cancer
-
批准号:7734411
-
项目类别:
-
资助金额:$17.55万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
MOUSE MODEL--TARGETED GENE KNOCK-OUT OF PROSTAGLANDIN SYNTHASE I AND II
-
批准号:6106581
-
项目类别:
-
资助金额:$0.0万
-
财政年份:--
-
负责人:Robert Langenbach
-
依托单位:
国内基金
海外基金
登录
查看更多内容
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
-
批准号:LBY21H010001
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2020
-
负责人:郑绪阳
-
依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
-
批准号:81703335
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:卫高菲
-
依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
-
批准号:81670594
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2016
-
负责人:陈昊
-
依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
-
批准号:81470791
-
项目类别:面上项目
-
资助金额:73.0万元
-
批准年份:2014
-
负责人:董家鸿
-
依托单位:
Apoptosis signal-regulating kinase 1是七氟烷抑制小胶质细胞活化的关键分子靶点?
-
批准号:81301123
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2013
-
负责人:王海莲
-
依托单位:
APO-miR(multi-targeting apoptosis-regulatory miRNA)在前列腺癌中的表达和作用
-
批准号:81101529
-
项目类别:青年科学基金项目
-
资助金额:22.0万元
-
批准年份:2011
-
负责人:陈雪芹
-
依托单位:
放疗与细胞程序性死亡(APOPTOSIS)相关性及其应用研究
-
批准号:39500043
-
项目类别:青年科学基金项目
-
资助金额:9.0万元
-
批准年份:1995
-
负责人:梁克
-
依托单位: